A study published in the International Journal of Dermatology has reported that patients treated with a high dose of intralesional triamcinolone (ILTAC) for hidradenitis suppurativa (HS) have expressed improvements in disease state, quality of life, and overall satisfaction.
While ILTAC is acknowledged as the standard of care for acute inflammation and drainage associated with HS, the study emphasized that optimal therapeutic doses have not been determined. Therefore, they opted for a high‐dose of ILTAC at 20 mg/ml (ILTAC‐20) or 40 mg/ml (ILTAC‐40) to investigate the utility and treatment of HS inflammatory lesions.
Between April and December 2018, patients with HS (Hurley stage I-III) treated with high-dose ILTAC-20 or ILTAC-40 were added to a retrospective chart review and telephone questionnaire. The questionnaire was short and examined satisfaction with therapy, changes of disease state, and modifications in quality of life. Data were obtained from electronic medical records and telephone interviews.
In total, 54 patients were interviewed. The average patient age was 36.9 ± 11.6 years, and two-thirds were female. According to the questionnaire, 40 (76.9%) patients were either very satisfied (n=19) or satisfied (n=21) with high-dose ILTAC therapy. A majority of patients (n=50, 92.6%) demonstrated improvements in disease state, and 41 (75.9%) experienced enhanced quality of life. When asked if they would be open to receiving additional injections of high-dose ILTAC if clinically indicated, 44 (86.3%) patients said they would be amenable to future treatments. No adverse effects of therapy were reported.
The authors concluded that high-dose ILTAC for acute lesions of HS is highly supported by the questionnaire results. —Jessica Garlewicz
Reference
Garelik J, Babbush K, Ghias M, Cohen SR. Efficacy of high-dose intralesional triamcinolone for hidradenitis suppurativa. Int J Dermatol. 2021;60(2):217-221. doi:10.1111/ijd.15124
